Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity

v3.22.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Beginning balance (in shares) at Dec. 31, 2020 290,300,547        
Beginning balance at Dec. 31, 2020 $ 763,283        
Increase (Decrease) in Temporary Equity [Roll Forward]          
Issuance of series U-1 redeemable convertible preferred stock at $9.06 per share in relation to acquisition (in shares) 110,437,359        
Issuance of Series U-1 redeemable convertible preferred stock at $9.06 per share in relation to acquisition $ 1,000,000        
Issuance of series U-2 redeemable convertible preferred stock at $9.06 per share, net of issuance costs of $2,138 (in shares) 44,174,944        
Issuance of Series U-2 redeemable convertible preferred stock at $9.06 per share, net of issuance cots of $2,138 $ 397,862        
Ending balance (in shares) at Mar. 31, 2021 444,912,850        
Ending balance at Mar. 31, 2021 $ 2,161,145        
Beginning balance (in shares) at Dec. 31, 2020   278,810,627      
Beginning balance at Dec. 31, 2020 (276,579) $ 3 $ 59,181   $ (335,763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock in relation to acquisitions (in shares)   257,863,127      
Issuance of common stock in relation to acquisitions 937,669 $ 2 937,667    
Purchase consideration allocated to non-cash severance expense 7,873   7,873    
Issuance of common stock upon exercise of stock options (in shares)   950,236      
Issuance of common stock upon exercise of stock options 702   702    
Vesting of early exercised stock options (in shares)   491,151      
Vesting of early exercised stock options 111   111    
Vesting of restricted stock (in shares)   1,429,340      
Stock-based compensation 39,040   39,040    
Comprehensive loss (188,619)       (188,619)
Ending balance (in shares) at Mar. 31, 2021   539,544,481      
Ending balance at Mar. 31, 2021 $ 520,197 $ 5 1,044,574   (524,382)
Beginning balance (in shares) at Dec. 31, 2021 0        
Beginning balance at Dec. 31, 2021 $ 0        
Ending balance (in shares) at Mar. 31, 2022 0        
Ending balance at Mar. 31, 2022 $ 0        
Beginning balance (in shares) at Dec. 31, 2021   1,122,829,814      
Beginning balance at Dec. 31, 2021 3,341,702 $ 11 4,432,907 $ 0 (1,091,216)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   4,338,152      
Issuance of common stock upon exercise of stock options 2,026   2,026    
Vesting of early exercised stock options (in shares)   35,503      
Vesting of early exercised stock options 11   11    
Vesting of restricted stock (in shares)   378,087      
Stock-based compensation 29,247   29,247    
Comprehensive loss (78,483)     (1,675) (76,808)
Ending balance (in shares) at Mar. 31, 2022   1,127,581,556      
Ending balance at Mar. 31, 2022 $ 3,294,503 $ 11 $ 4,464,191 $ (1,675) $ (1,168,024)